$INMD

4 stories mentioning INMDUpdated just now

Every FINWIRES story that references INMD, newest first.

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index adding 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.9%.The iShares Biotechnology ETF (IBB) climbed 2.4%.In corporate news, Eli Lilly (LLY) and Bayer's pharmaceutical division have backed the Trump administration's call for higher drug prices in Europe, the Financial Times reported. Separately, Lilly said Wednesday it has completed its acquisition of Centessa Pharmaceuticals. Lilly shares were up 0.6%.NRx Pharmaceuticals (NRXP) and two units are facing a lawsuit from Kadima Neuropsychiatry Institute for alleged breach of contract and misrepresentation regarding an acquisition agreement, the psychiatric clinic said Wednesday. NRx Pharmaceuticals shares fell 12%.Pfizer (PFE) has been dismissed as a defendant in a lawsuit brought by 45 US states, the District of Columbia, and 4 US territories that accused drugmakers and executives of fixing generic drug prices, Reuters reported. Its shares were down 2.4%.InMode (INMD) board received an unsolicited acquisition proposal last week for all shares not already owned by M.N. Business Strategy for $16.20 per share in cash, the medical technology firm said Wednesday. The shares jumped 10%.

$INMD$LLY$NRXP$PFE

Sectors3h ago

Sector Update: Healthcare Stocks Advance Wednesday Afternoon

Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index adding 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.3%.The iShares Biotechnology ETF (IBB) climbed 2.2%.In corporate news, InMode (INMD) board received an unsolicited acquisition proposal last week for all shares not already owned by M.N. Business Strategy for $16.20 per share in cash, the medical technology firm said Wednesday. Shares jumped 11%.Pfizer (PFE) has been dismissed as a defendant in a lawsuit brought by 45 US states, the District of Columbia, and 4 US territories that accused drugmakers and executives of fixing generic drug prices, Reuters reported. Shares were down 3.1%.Eli Lilly (LLY) and Bayer's pharmaceutical division have backed the Trump administration's call for higher drug prices in Europe, the Financial Times reported. Separately, Lilly said Wednesday it has completed its acquisition of Centessa Pharmaceuticals. Lilly shares were shedding 0.5%.

$INMD$LLY$PFE

Sectors4h ago

Sector Update: Healthcare

Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 0.6%.The iShares Biotechnology ETF (IBB) climbed 2.5%.In corporate news, InMode (INMD) board received an unsolicited acquisition proposal last week for all outstanding shares not already owned by M.N. Business Strategy for $16.20 per share in cash, the medical technology company said Wednesday. InMode shares jumped 12%.

$INMD

Wire49d ago

InMode Share Fall After Q1 Non-GAAP Earnings Miss Estimates

InMode's (INMD) shares were down more than 6% in Wednesday trading after the company reported Q1 results that missed analyst expectations on earnings and issued a weaker-than-expected 2026 earnings outlook.The company reported Q1 non-GAAP earnings of $0.25 per diluted share, down from $0.31 a year earlier.Analysts polled by FactSet expected $0.29.Revenue for the quarter ended March 31 was $82 million compared with $77.9 million a year earlier.Four analysts surveyed by FactSet expected $80.3 million.The company said it now expects 2026 adjusted EPS in a range of $1.33 to $1.38, down from its previous guidance of $1.43 to $1.48. Analysts surveyed by FactSet expect $1.45.The company maintained its annual revenue guidance of between $365 million and $375 million. Analysts polled by FactSet expect $370 million.Price: $13.38, Change: $-1.02, Percent Change: -7.08%

$INMD

Track with the FINWIRES app suite

FolioX

Track INMD in your portfolio

WheelAI

Analyze INMD options with the wheel strategy

StockInsider

See market sentiment on INMD